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Abstract
Background: The immune-
modulating drug, infl iximab, is 
approved for Infl ammatory Bowel 
Disease (IBD) treatment in children. 
Chronic therapy with infl iximab is 
associated with the development of 
early and delayed infusion reactions. 
We reviewed our experience with 
infl iximab treatment and its side 
effects in a cohort of children 
diagnosed with IBD who were treated 
in our clinic. 
Methods: A retrospective analysis of 
all IBD children treated with 
infl iximab in our center from 2006-
2011 was performed. The 
demographic, chronological and 
clinical data were recorded. The 
infi ximab infusion was given at 5mg/
kg according to a standard protocol 
after pre-treatment with low dose 
steroid and diphenhydramine. 
Results: Of 30 IBD patients (23 
CD/7 UC) receiving 454 infusions (341 
CD/113 UC), six (20%) patients 
experienced early infusion reactions. 
Two (6.7%) patients had a delayed 
reaction; of those, both required 
intestinal resection. 
Conclusion: Our study is the fi rst to 
address the safety of infl iximab 
infusion reactions in children in the 
state of WV. Our results lend support 
to the use and safety of infl iximab in 
children with moderate to severe IBD.
Introduction
Infl ammatory Bowel disease 
(IBD) consists of ulcerative colitis 
(UC), Crohn’s disease (CD), 
or intermediate colitis (IC). An 
estimated 1-1.5 million people in the 
US have ulcerative colitis or Crohn’s 
disease.1 The most common clinical 
symptoms of IBD in children include 
bloody stools, weight loss, fatigue, 
abdominal cramping, increased 
frequency of bowel movements, 
and fever.2 Crohn’s disease is 
histologically characterized by non-
caseating granulomas, transmural 
infl ammation, cobblestone-
type mucosa, and bowel wall 
thickening.3 The etiology of IBD 
is related to a combination of 
immune dysregulation and chronic 
infl ammation, leading to bleeding 
of the mucosa.3 TNF-alpha is an 
important cytokine central to the 
infl ammatory process of IBD. 
Macrophages, mast cells, and 
activated T-helper cells (particularly 
TH1 cells) are responsible for 
the secretion of TNF-alpha.3 
The treatment of IBD is based 
on the severity of the disease. For 
mild IBD, aminosalicylates and 
antibiotics are used.4,5 For more 
severe cases, immuno-suppressive 
drugs, such as azathioprine or 
methotrexate, are utilized. For 
refractory cases, the biological 
drugs such as anti-TNF-alpha 
medications [infl iximab (Remicade), 
adalimumab (Humira)] or other 
investigational drugs may be used.
Infl iximab is an anti-TNF-alpha 
drug administered by IV for the 
treatment of children with moderate/
severe IBD. It is a monoclonal 
anti-TNF IgG molecule composed 
of part human and part mouse-
derived TNF-alpha binding regions 
(chimeric).6 Infl iximab binds to 
TNF-alpha with high affi nity and 
specifi city and blocks free TNF-
alpha in the serum.6 The drug also 
affects TNF-alpha molecules that 
are attached to target cells such 
as the intestinal enterocytes.6 
Anti-TNF medications have been 
approved for the treatment of IBD 
in children. Furthermore, chronic 
therapy with these drugs is usually 
required and may be associated 
with the development of early 
or delayed infusion reactions.
In the present study, we reviewed 
the early and delayed adverse 
events associated with infl iximab 
infusion in a cohort of IBD children 
followed in our medical center. 
Material and Methods
A cohort of children diagnosed with 
IBD, who were treated with infl iximab 
at Marshall University Department 
of Pediatrics, Gastroenterology 
Division, between 2006-2011, 
was included in our study. 
Demographic, clinical symptoms, 
and infusion reaction data were 
recorded from the patients’ 
charts. Per the recommended 
clinical guideline, all patients were 
screened negative to TB testing 
(Mantou test) before initiation 
of infl iximab therapy. Infl iximab 
infusion was given per written 
standard protocol that included 
pre-administration (IV) of low dose 
steroid and diphenhydramine. The 
recommended dose of infl iximab for 
pediatric patients 6 years and older 
with moderately to severely active 
Crohn’s disease or ulcerative colitis 
was given as follows: induction dose 
of 5 mg/kg given IV at 0, 2, and 6 
weeks, followed by maintenance 
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regimen at 5 mg/kg. Patients initially 
received the infusion every 8 weeks, 
but the frequency was changed 
to every 6 weeks according to the 
clinical response of the patient. 
An early infusion reaction was 
defi ned as either hypersensitivity or 
an anaphylactic reaction occurring 
during the infusion, immediately 
post-infusion, or up to three days 
post-infusion. Early infusion 
reactions consisted of facial fl ushing, 
fevers and chills, pruritus, heart 
rate changes and other symptoms 
as outlined in Table 1. A delayed 
adverse event was defi ned as a 
reaction that occurred 3-12 days 
after the infusion.7 Those events may 
include respiratory infections (i.e. TB) 
and/or other serious infections (intra-
abdominal abscesses, opportunistic 
infections), pseudo-membranous 
colitis, gastroenteritis, thyroiditis, 
pancreatitis, seizures, psoriasis, 
pneumonia, or appendicitis.7 
Results
Thirty patients were included 
in the study, of whom 23 had 
CD and 7 had UC. A total of 454 
infusions were given during the 
study period; 341 infusions were 
given to the CD patients and 113 
were given to the UC patients. 
Experimental data and infusion 
data are described in Table 2. In 
26 of the 454 total infusions, a 
total of six patients experienced 
early infusion reactions and two 
experienced delayed adverse 
events. Six IBD patients experienced 
early infusion reactions associated 
with hypersensitivity (itching, facial 
fl ushing, chest tightness and/or 
shortness of breath). All responded 
to decreased infusion rate and 
completed their therapy uneventfully. 
Table 1. Common reactions to infl iximab infusion.
Early infusion reactions (1-3 days post infusion) Delayed Adverse events (3-12 days post infusion)
Hypersensitivity reactions and anaphylaxis associated 
with facial fl ushing, shortness of breath, chest tightness, 
pruritus, tachy/bradycardia, hives, nausea/vomiting/
diarrhea, seizures
Tuberculosis, intra-abdominal abscesses, opportunistic 
infections, pseudo-membranous colitis, Hodgkin’s lymphoma, 
upper respiratory infections, pharyngitis, neutropenia, 
thyroiditis, pancreatitis, seizures, psoriasis, bronchitis, 
pneumonia, bacterial infection, abnormal LFTs, appendicitis
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A delayed adverse event (intra-
abdominal abscess) was seen in 
2 CD patients; in both cases an 
intestinal resection was needed. 
Discussion
Anti-biological drugs, such as 
infliximab and adalimumab, are 
very potent medications for children  
with IBD. Results have shown that 
since these drugs were approved 
for this disease by the Food and 
Drug Administration (FDA), the 
entire prognosis of IBD patients 
has dramatically improved; the 
remission rate has increased and 
the hospitalization rate and number 
of operations have decreased.8,9,10 
As with all potent medications, 
the side effects of these drugs 
are significant, including: immune 
suppression, secondary infection 
(viral, TB and more), autoimmune 
disease (arthritis and psoriasis), and 
cancer development (lymphoma and 
hepato-splenic T cell lymphoma).7 
In addition to these effects, there is 
increasing evidence of the reactions 
associated with the infusion itself. 
In a recent multicenter registry, the 
infusion-related side effects were 
described in 533 pediatric patients 
who had a total of 6914 infusions.11 
In that report, 72 (13.5%) patients 
experienced early infusion reactions 
associated with facial flushing and 
shortness of breath. In the same 
study, delayed adverse events 
occurred in 38 patients, including 7 
(1.3%) with pancreatitis, 13 (2.4%) 
with psoriasis, 4 with abnormal 
LFT’s, 10 with opportunistic 
infections, 1 with neutropenia, 
and 2 with seizures.11 One patient 
developed Hodgkin’s lymphoma 
of the bowel. No intra-abdominal 
abscesses were reported. Hyams 
et al studied 60 patients receiving 
670 infusions, of which 14 patients 
(23%) developed early infusion 
reactions.7 Delayed adverse 
events developed in 46 (77%) 
patients, including upper respiratory 
infections, pharyngitis, bronchitis 
or pneumonia. Severe adverse 
events were noted in 20 (33.3%) 
patients, which included an intra-
abdominal abscess, appendicitis, 
pneumonia, gastroenteritis, 
pseudomembranous colitis, and/
or bacterial infection.7 In our small 
cohort, only six (20%) patients 
developed early infusion reactions 
and two (6.7%) experienced delayed 
adverse events (Table 1). The 
rate of early infusion reaction was 
higher in our study compared to 
Markowitz et al (20% vs. 13.5%, 
respectively), but the latter study 
was a collection of data from a 
registry list collected from multiple 
clinical centers, while our data was 
derived from a single center from 
WV. When we compared our data 
to a single center report (i.e. the 
study from a center in Connecticut), 
our early infusion reaction rate was 
lower (20% vs. 33%).7 Additionally, 
it has been documented that 
approximately 10-30% of patients 
suffering from Crohn’s disease 
can expect an abdominal or pelvic 
abscess to develop spontaneously 
during the course of their disease 
without ever receiving an infusion 
of infliximab.12 Thus, it is possible 
that the abscesses reported in our 
patients were developed as a result 
of the illness itself. Nonetheless, 
no patients in our study developed 
abscesses before starting the 
treatment with infliximab suggesting 
that the drug was a major contributor 
to the abscess development. 
Additionally, the low rate of overall 
adverse events (26/454 infusions, 
5.7%) noted in our study may 
partially be related to the pre-
treatment infusion of steroid and 
diphenhydramine. A pre-medication 
regimen was not described in the 
previously cited multicenter study, 
but other reports have supported this 
practice.13,14 In addition, to reduce 
complications, it is important to 
follow the infusion protocol closely to 
include gradual increase/decrease 
of the infusion rate followed by a 
close monitoring of the patients.
Our pilot study is limited by 
the small number of patients and 
the retrospective nature of the 
investigation. Further research 
could include a multi-center study in 
Table 2. Infliximab infusions and reactions for Crohn’s disease and ulcerative colitis patients. 
Diagnosis Crohn’s Disease Ulcerative Colitis
No. pts (M/F) 23 (13/10) 7 (6/1)
Age of patients at conclusion of study (mean) 16.7 16.3
No. infusion (total) 341 113
No. infusion/ pt (Mean + SD) 14.7+ 11 14.1+ 9.5
No. infusion/ pt [Median (range)] 15 (1-35) 11 (3-27)
Early infusion reaction 5 1
Delayed adverse event 2 0
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the state. Nevertheless, our study 
demonstrated encouraging results 
that lend support to the safety of 
infliximab in children diagnosed with 
IBD. Our data support the notion 
that infliximab treatment for children 
in WV is safe and feasible. To our 
knowledge, this is the first report of 
infliximab infusion adverse events 
in children from West Virginia. 
In conclusion, we find the 
infusion of infliximab to be safe in 
children with moderate to severe 
IBD, particularly when preventive 
measures are taken to minimize 
or stop the progression of infusion 
reactions. Our data suggest that 
our patient population should not 
seek out-of-state medical services 
for intravenous infliximab therapy, 
and that such therapy is available at 
various GI centers within the state. 
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